Trial · NCT02799485
sEphB4-HSA in Treating Patients With Kaposi Sarcoma
NCT02799485, Phase 2, Completed, AIDS Malignancy Consortium
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. sEphB4-HSA in Treating Patients With Kaposi Sarcoma. Trials, record NCT02799485. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02799485
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- sEphB4-HSA in Treating Patients With Kaposi Sarcoma
- NCT number
- NCT02799485
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 23 participants, actual
- Lead sponsor
- AIDS Malignancy Consortium
- Conditions
- Skin Kaposi Sarcoma
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Recombinant EphB4-HSA Fusion Protein
- First posted
- 2016-06-15
- Last updated
- 2026-06-01
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants Experiencing Clinical Response | Up to 12 months (end of follow-up) | The observed proportions of participants experiencing clinical response will be calculated with 95% confidence intervals. |
| Secondary | Safety of sEphB4-HSA | Up to 12 months (end of follow-up) | The number of participants with adverse events will be reported. |
| Secondary | Trough Levels of Recombinant sEphB4-HSA Fusion Protein | Up to Cycle 12 of treatment | Descriptive statistics and graphical displays will be used to evaluate correlation between response and trough levels of sEphB4-HSA. Depending on the number enrolled, the association between clinical response and changes in trough levels, pharmacodynamic endpoints, viral copy number, protein expression and activation status, and finally immune cell counts and activation status will be investigated using the nonparametric Wilcoxon rank sum test. |
| Secondary | Viral Replication of HHV-8 of Recombinant sEphB4-HSA Fusion Protein | Up to Cycle 12 of treatment | Descriptive statistics and graphical displays will be used to evaluate correlation between response and pharmacodynamics of sEphB4-HSA. Depending on the number enrolled, the association between clinical response and changes in viral replication of HHV-8 will be investigated using the nonparametric Wilcoxon rank sum test. |
| Secondary | Gene Expression of HHV-8 of Recombinant sEphB4-HSA Fusion Protein | Up to Cycle 12 of treatment | Descriptive statistics and graphical displays will be used to evaluate correlation between response and pharmacodynamics of sEphB4-HSA. Depending on the number enrolled, the association between clinical response and changes in gene expression will be investigated using the nonparametric Wilcoxon rank sum test. |
| Secondary | Immune Response and Modulation of Recombinant sEphB4-HSA Fusion Protein | Up to Cycle 12 of treatment | Descriptive statistics and graphical displays will be used to evaluate correlation between response and pharmacodynamics of sEphB4-HSA. Depending on the number enrolled, the association between clinical response and changes in immune cell counts will be investigated using the nonparametric Wilcoxon rank sum test. |
| Other | Overall Quality of Life, Assessed Using the KS Functional Assessment of HIV Questionnaire | Up to12 months (Post-treatment evaluation) | Five measures of overall quality of life will be scored: physical well-being (0-40), emotional well-being (0-40), functional and global well-being (0-52), social well-being (0-32), and cognitive functioning (0-12). The total score is the sum of the five subdomains and ranges from 0 to 176. For KS-specific symptoms, responses may be dichotomized to reflect their positive or negative impact. General estimating equations using a log-binomial model will be used to assess changes in these symptoms over time. For all subdomains and total scores, higher scores indicate better health-related quality of life (HRQoL). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01CA121947 | AIDS Malignancy Clinical Trials Consortium (AMC) | MITSUYASU, RONALD T. | UNIVERSITY OF CALIFORNIA LOS ANGELES | NATIONAL CANCER INSTITUTE | 2006 to 2014 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02799485
GET https://conductscience.org/api/trials/v1/NCT02799485/registered